It appears you have not yet Signed Up with our community. To Sign Up for free, please click here....

Multiple Sclerosis Message Board

NeuroVax- Quarterly Drug

Post New Thread   Closed Thread
LinkBack Thread Tools Search this Thread
Old 04-01-2005, 10:07 PM   #1
Moon Rising
Senior Member
Join Date: Mar 2005
Posts: 165
Moon Rising HB User
Exclamation NeuroVax- Quarterly Drug

Vaccine for multiple sclerosis, NeuroVax™ is an immune-based therapy designed to specifically down-regulate the body’s destructive immune responses observed in MS patients to alleviate the impact of the disease.

“The NeuroVax™ data we’ve seen thus far lead us to believe that it may have a clinical benefit for MS patients and we are excited to begin this new Phase II study to provide additional important information about the therapy’s mechanism-of-action and long-term safety,” said John N. Bonfiglio, Ph.D., President and Chief Executive Officer of The Immune Response Corporation.

Last year, the Company presented data demonstrating that NeuroVax™ produced a peptide-specific immune response in 94 percent of the patients treated in a Phase I/II clinical trial in MS. A separate open-label rollover study has now completed enrollment and is currently following those patients to evaluate the long-term safety of NeuroVax™. The new Phase II study announced today will build on the knowledge acquired in these studies and seek to further understand the mechanism-of-action of NeuroVax™ and explore possible dosing regimens.

“This new Phase II study is designed to examine the durability of the immunological responses we’ve seen in patients receiving NeuroVax™,” said Georgia Theofan, Ph.D., Vice President of Clinical Development at The Immune Response Corporation. “We may be able to successfully maintain these responses with a quarterly dosing regimen which would be an important benefit to patients.”

The new open-label study will ultimately enroll 40 patients with relapsing remitting or secondary progressive multiple sclerosis, of which approximately 30 will be rollover patients from a previous study. Patients in this new study will receive three monthly NeuroVax™ injections followed by three quarterly injections. Enrollment is expected to be completed by spring 2005 and results are expected in 2006.

The Company’s strategy for the development of NeuroVax™ includes not only the expansion and completion of the current and new Phase II trials, but also the initiation in summer 2005 of a large placebo controlled trial designed with magnetic resonance imaging (MRI) and clinical endpoints to examine the clinical benefit of NeuroVax™. The Company also intends to search for a corporate partner to help take this program to commercialization

Sponsors Lightbulb
Closed Thread

Similar Threads
Thread Thread Starter Board Replies Last Post
N E U R O V A X Piano Man Multiple Sclerosis 5 12-11-2007 03:16 PM

Thread Tools Search this Thread
Search this Thread:

Advanced Search

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is Off
HTML code is Off
Trackbacks are Off
Pingbacks are Off
Refbacks are Off

Sign Up Today!

Ask our community of thousands of members your health questions, and learn from others experiences. Join the conversation!

I want my free account

All times are GMT -7. The time now is 09:51 PM.

Site owned and operated by™
© 1998-2018™ All rights reserved.
Do not copy or redistribute in any form!